Drug Trial Radar · NCT04988555
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
606
Planned (sponsor's estimate)
Start
Feb 28, 2022
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Conditions
- Leukemia, Myeloid, Acute
- Leukemia, Lymphocytic, Acute
- Multiple Myeloma
- Myelodysplastic Syndromes
Interventions
EnzomenibDrug
DSP-5336 orally
azolesDrug
Posaconazole, Voriconazole, or Fluconazole
VenetoclaxDrug
Venetoclax orally
GilteritinibDrug
Gilteritinib orally
Azacitidine (AZA)Drug
Azacitidine orally
Intensive chemotherapy with 7 + 3Drug
chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with adverse events and serious adverse events in Phase 1Time frame: 30 days from last dose
- Determination of Recommended Phase 2 Dose (RP2D)Time frame: Within 4 months from first dose
- Determination of Recommended Phase 2 Dose (RP2D) for patients with relapse and refractory AML who are enrolled into the combination venetoclax and azacitidine armTime frame: Within 4 months from first dose
- Determination of Recommended Phase 2 Dose (RP2D) for patients with relapse and refractory AML who are enrolled into the gilteritinib armTime frame: Within 4 months from first dose
- Optimal dose of DSP-5336 (RP2D) for patients newly diagnosed with AML enrolled into the combination venetoclax and azacitidine armTime frame: Within 4 months from the first dose
- Determination of Recommended Phase 2 Dose (RP2D) for patients enrolled into the 7 + 3 armTime frame: Within 4 months from first dose
- Number of patients achieving complete response (CR) and complete response with partial hematologic recovery (CRh) in Phase 2Time frame: Approximately 6 months after first dose
Locations
104 sites in 12 countries. Site status is shown where the registry gives one.
Hoag Family Cancer Center
Newport Beach, California · Recruiting
Stanford University
Palo Alto, California · Not yet recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Not yet recruiting
University of Miami
Miami, Florida · Recruiting
Miami Cancer Institute
Miami, Florida · Not yet recruiting
Moffitt Cancer Center
Tampa, Florida · Not yet recruiting
Northwestern
Chicago, Illinois · Recruiting
Sibley Memorial Hospital
Baltimore, Maryland · Recruiting
University of Maryland
Baltimore, Maryland · Recruiting
Johns Hopkins Main Center
Baltimore, Maryland · Recruiting
Tufts University
Boston, Massachusetts · Withdrawn
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Atlantic Health
Morristown, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Mount Sinai Hospital
New York, New York · Completed
Columbia University
New York, New York · Completed
UNC Hospital
Chapel Hill, North Carolina · Recruiting
Duke University
Durham, North Carolina · Recruiting
Atrium Wake Forest Baptist Medical Center
Winston-Salem, North Carolina · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Oncology Associates of Oregon
Eugene, Oregon · Recruiting
Sidney Kimmel Comprehensive Cancer Center
Philadelphia, Pennsylvania · Recruiting
Allegheny Health Network
Pittsburgh, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
TriStar Centennial Medical Center
Nashville, Tennessee · Recruiting
MDACC
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Intermountain Healthcare
Salt Lake City, Utah · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
ZNA Cadix
Antwerp, Belgium · Recruiting
UZ Ghent
Ghent, Belgium · Recruiting
University Hospitals Leuven
Leuven, Belgium · Recruiting
AZ Delta
Roeselare, Belgium · Recruiting
University of Alberta
Edmonton, Canada · Recruiting
Tom Baker Cancer Center
Calgary, Alberta, Canada · Recruiting
Centre Hospitalier Universitaire d'Angers
Angers, France · Recruiting
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.